Jafron Biomedical Co Ltd (300529.SZ) stock: key figures, P/E, revenue and dividend
Health Care · Health Care Equipment · China · ISIN CNE100002995
Jafron Biomedical Co Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 2.68 bn CNY | 2.01 bn CNY |
| Gross profit | 2.16 bn CNY | 1.58 bn CNY |
| Operating income | 1.05 bn CNY | 739.52 m CNY |
| EBIT | 997.98 m CNY | 713.64 m CNY |
| Net income | 820.20 m CNY | 532.82 m CNY |
| Diluted EPS – continuing operations | 1.07 CNY | 0.67 CNY |
Full history since 2011, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Jafron Biomedical Co Ltd
Jafron Biomedical Co.,Ltd. engages in the research, development, production, and sale of blood purification products for hemadsorption field worldwide. The company offers therapies for kidney, liver, and critical diseases, as well as poisoning. It also provides HA series disposable hemoperfusion cartridge; BS series disposable plasma bilirubin perfusion adsorption column; blood purification machine; and other products, such as JM hemodialyzer, DNA230, disinfectant, hemodialysis concentrate, resin bandage, online hemodialysis B powder bag/bucket, PGA absorbable suture with needle, syringe and infusion pumps. The company was founded in 1989 and is based in Zhuhai, China.
More stocks
- EPLUS INC (PLUS)
- Compagnie Financiere Tradition SA (CFT.SW)
- Tongling Jingd (600577.SS)
- Rede Energia Participações S.A (REDE3.SA)
- Multiplan Empreendimentos Imobiliários S.A (MULT3.SA)
- PELOTON INTERACTIVE, INC. (PTON)
- Shanghai Kingstar Winning Software (300253.SZ)
- Under Armour, Inc. (UA)
- TX Group AG (TXGN.SW)
- Lancashire Holdings Ltd (LRE.L)
- Zhejiang Semir Garment Co Ltd (002563.SZ)
- Pou Chen Corp (9904.TW)
Not investment advice. All data without warranty, price as of 03.11.2026. Details in the risk notice.